An Arrowhead Research official this week denied reports that concerns over potency or toxicity have prompted the company to expand a phase I trial of its investigational hepatitis B treatment ARC-520, which has just moved into phase IIa testing.

According to Vince Anzalone, vice president of finance at Arrowhead, "regulators did not ask us to go back to dose more healthy volunteers and there were no safety signals of concern" in the phase I study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.